Tevogen bio broadens relationship with microsoft to deepen artificial intelligence collaboration and develop predictcell technology on azure

Warren, n.j., jan. 24, 2025 (globe newswire) -- tevogen bio holdings inc. (“tevogen bio” or “company”) (nasdaq: tvgn ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified t-cell therapeutics for infectious diseases and cancers, announced today that it has broadened its relationship with microsoft (nasdaq: msft ) to broaden its ai-focused collaboration and build its predictcell technology. predictcell is tevogen bio's proprietary technology designed for predictive precision t cell targeting. this expanded relationship is designed to harness microsoft's cutting-edge ai, cloud capabilities, and microsoft's health and life sciences domain expertise to accelerate tevogen bio's target identification and pre-clinical processes, strengthening the company's pipeline of innovative immunotherapies.
MSFT Ratings Summary
MSFT Quant Ranking